In his weekly clinical update, Daniel Griffin and Vincent Racaniello reviewed the latest developments surrounding the hantavirus outbreak, including new interim guidance from the Centers for Disease Control and Prevention for the management of infectious cases, whether the CDC may be downplaying the significance of the outbreak because of public backlash following the COVID-19 pandemic, before Dr. Griffin deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, benefit of maternal vaccination against RSV for infants, efficacy and safety of a mRNA influenza vaccine  how to access and pay for Paxlovid, where to go for answers about long COVID-19, multisystem inflammatory syndrome in children and contacting your federal government representative to stop the assault on science and biomedical research.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Interim Guidance for Public Health Assessment and Management of People with Potential Exposure to Andes Virus Outbreak (CDC)
• Hantavirus in humans: a review of clinical aspects and management (LANCET: Infectious Diseases)
• “Super-Spreaders” and Person-to-Person Transmission of Andes Virus in Argentina (NEJM)
• Person-to-Person Transmission of Andes Virus in Hantavirus Pulmonary Syndrome, Argentina, 2014 (CDC: Emerging Infectious Diseases)
• Hantavirus on board with Prof. Vincent Racaniello (microbeTV)
• Transcript – Updateon CDC’s Hantavirus Response 5/13/2026 (CDC)
• CDC Is Walking a Tightrope With Its Response to Hantavirus (Wall Street Journal)
• What Happened on the Hantavirus Cruise, According to a Doctor On Board (The Atlantic)
• Andes hantavirus outbreak on a cruise ship – an ESCMID Emerging Infections Subcommittee (EIS) rapid assessment (CMI: Clinical Microbiology and Infection)
• Wastewater for measles (WasterWater Scan)
• Measles cases and outbreaks (CDC Rubeola)
• Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health)
• Utah measles outbreak response (Utah Department of Health and Human Services)
• Utah Measles Dashboard (Utah Department of Health and Human Services)
• Tracking Measles Cases in the U.S. (Johns Hopkins)
• Measles vaccine recommendations from NYP (jpg)
• Weekly measles and rubella monitoring (Government of Canada)
• Measles (WHO)
• Get the FACTS about measles (NY State Department of Health)
• Measles (CDC Measles (Rubeola))
• Measles vaccine (CDC Measles (Rubeola))
• Presumptive evidence of measles immunity (CDC)
• Contraindications and precautions to measles vaccination (CDC)
• Adverse events associated with childhood vaccines: evidence bearing on causality (NLM)
• Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America)
• Deaths following vaccination: what does the evidence show (Vaccine)
• Influenza: Waste water scan for 11 pathogens (WastewaterSCan)
• USrespiratory virus activity (CDC Respiratory Illnesses)
• Respiratory virus activity levels (CDC Respiratory Illnesses)
• Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA)
• WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP)
• FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP)
• Weekly surveillance report: cliff notes (CDC FluView)
• Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults (NEJM)
• OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza)
• RSV: Waste water scan for 11 pathogens (WastewaterSCan)
• Respiratory Diseases (Yale School of Public Health)
• US respiratory virus activity (CDC Respiratory Illnesses)
• RSV-Network (CDC Respiratory Syncytial virus Infection)
• Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV))
• Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP)
• Respiratory Diseases (Yale School of Public Health)
• Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial (Pediatrics)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 deaths (CDC)
• Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses)
• COVID-19 national and regional trends (CDC)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England (PLoS One)
• Where to get pemgarda (Pemgarda)
• EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD)
• Infusion center (Prime Fusions)
• Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts (NEJM)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Drug interaction checker (University of Liverpool)
• Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro)
• Understanding Coverage Options (PAXCESS)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• Managing healthcare staffing shortages (CDC)
• Anticoagulation guidelines (hematology.org)
• Daniel Griffin’s evidence based medical practices for long COVID (OFID)
• Long COVID hotline (Columbia : Columbia University Irving Medical Center)
• The answers: Long COVID
• Reaching out to US house representative
• Letters read on TWiV 1322
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene Ramsey. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Content in this podcast should not be construed as medical advice.